Drug Trial Radar · NCT01882803
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Jun 17, 2013
Primary completion
Nov 18, 2020
Study completion Nov 18, 2020
Sponsor
- Lead sponsor
- SecuraBioIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).
Conditions
- Indolent Non-Hodgkin Lymphoma
Interventions
DuvelisibDrug
Phosphoinositide-3-kinase (PI3K) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Every 8-16 weeks while on treatment with duvelisib for up to 72 months
Locations
69 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Fort Myers, Florida
Site not named
St. Petersburg, Florida
Site not named
Tallahassee, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Howell Township, New Jersey
Site not named
Morristown, New Jersey
Site not named
New York, New York
Site not named
Rockville Centre, New York
Site not named
Canton, Ohio
Site not named
Lawton, Oklahoma
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Lynchburg, Virginia
Site not named
Brest, Belarus
Site not named
Minsk, Belarus
Site not named
Vitebsk, Belarus
Site not named
Lyasny, Minsk Oblast, Belarus
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Toronto, Ontario, Canada
Site not named
Gatineau, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Brno, Czechia
Site not named
Ostrava-Poruba, Czechia
Site not named
Angers, France
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.